5 completed, 3 terminated. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Terminated 3 |
| Phase 1 | 2 | Completed 2 |
Follow namilumab: new trials by email Literature Review of namilumab trials Research Report on namilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis Namilumab, Placebo - Sarcoidosis, Pulmonary | Phase 2 | Terminated | Kinevant Sciences GmbH | 107 | 2022-08-31 | 2025-09-12 |
| A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis Namilumab - Sarcoidosis, Cardiac | Phase 2 | Terminated | Kinevant Sciences GmbH | 1 | 2022-08-23 | 2025-04-17 |
| Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis Placebo, Namilumab - Axial Spondyloarthritis | Phase 2 | Completed | Izana Bioscience Ltd. | 42 | 2018-09-06 | 2022-03-08 |
| Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate Namilumab, Adalimumab, Methotrexate - Rheumatoid Arthritis | Phase 2 | Terminated | Takeda | 7 | 2015-04-08 | 2019-02-05 |
| Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) Namilumab, Placebo, Methotrexate - Rheumatoid Arthritis | Phase 2 | Completed | Takeda | 108 | 2014-12-17 | 2018-09-14 |
| Single-Dose Study of MT203 MT203 80 mg or matching Placebo, MT203 150mg or matching Placebo, MT203 300 mg or matching placebo - Healthy Volunteers | Phase 1 | Completed | Takeda | 32 | 2014-11-01 | 2016-06-20 |
| Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis Namilumab, Placebo - Plaque Psoriasis | Phase 2 | Completed | Takeda | 122 | 2014-06-01 | 2017-04-07 |
| A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis namilumab (MT203), Placebo - Rheumatoid Arthritis | Phase 1 | Completed | Takeda | 24 | 2011-03-01 | 2015-08-20 |
Arthritis, Rheumatoid (3) · Axial Spondyloarthritis (1) · Sarcoidosis (1) · Sarcoidosis, Pulmonary (1)
Takeda (5) · Kinevant Sciences GmbH (2) · Izana Bioscience Ltd. (1)
United Kingdom (4) · Bulgaria (2) · Czechia (2) · Japan (2) · Netherlands (2) · Russia (2) · Spain (2) · United States (2) · Belgium (1) · Canada (1) · Estonia (1) · France (1) · Germany (1) · Poland (1) · South Korea (1)
PMID 28274253, PMID 30168415, PMID 30207587, PMID 30999929, PMID 38942047, PMID 41819539
2014 (1)